)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Intra-Cellular Therapies
Intra-Cellular Therapies (ITCI) investor relations material
Intra-Cellular Therapies has been delisted
Intra-Cellular Therapies Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary21 Feb, 2025
Executive summary
CAPLYTA net product sales reached $199.2M in Q4 2024, up 51% year-over-year; full-year 2024 sales were $680.5M, a 47% increase.
FDA accepted the sNDA for lumateperone as adjunctive treatment for major depressive disorder (MDD).
Field sales force expansion began in Q1 2025 in anticipation of potential MDD approval.
Financial highlights
SG&A expenses rose to $504.5M in 2024 from $409.9M in 2023, mainly due to commercialization and marketing.
R&D expenses increased to $236.1M in 2024 from $180.1M in 2023, reflecting higher project costs.
Cash, cash equivalents, investment securities, and restricted cash totaled $1.0B at year-end 2024, up from $499.7M at year-end 2023.
Net loss for Q4 2024 was $16.9M ($0.16/share); full-year net loss was $74.7M ($0.72/share), improved from $139.7M loss in 2023.
Outlook and guidance
Anticipates potential FDA approval and commercial launch of CAPLYTA for adjunctive MDD treatment.
Ongoing expansion of sales force to support expected growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Intra-Cellular Therapies
- CAPLYTA sales rose 86% in 2023, with 2024 guidance of $645–$675 million.ITCI
Q4 2023 - Caplyta's robust growth and broadening indications drive major expansion into mood disorder markets.ITCI2024 Cantor Fitzgerald Global Healthcare Conference
- Q3 2024 net sales up 39% year-over-year; guidance raised on strong growth and pipeline.ITCIQ3 2024
- CAPLYTA's strong growth and clinical success drive expansion into MDD and broader CNS markets.ITCIMorgan Stanley 22nd Annual Global Healthcare Conference
- CAPLYTA’s growth accelerates with new indications and a rich pipeline, backed by strong finances.ITCIBaird's 2024 Global Healthcare Conference
- MDD sNDA filing expected this year, with pipeline and sales force expansion progressing.ITCICanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
- Caplyta sales surged 46% in Q2 2024, driving improved results and a higher 2024 outlook.ITCIQ2 2024
- Lumateperone showed robust efficacy and safety as adjunctive therapy in MDD Phase 3 trials.ITCIStudy Result
- CAPLYTA's growth accelerates with new indications, pivotal trials, and strong financials.ITCIJefferies 2024 Global Healthcare Conference
- Strong growth in mood disorders, pipeline expansion, and robust prescriber base drive outlook.ITCIGoldman Sachs 45th Annual Global Healthcare Conference
Intra-Cellular Therapies
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Intra-Cellular Therapies Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments for central nervous system disorders. The company develops therapies targeting neuropsychiatric and neurological conditions using its proprietary research platform. Its product portfolio includes both marketed treatments and pipeline candidates addressing various mental health and neurological diseases. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.